Miltenyi Biotec
keyboard_backspaceBack to Home
Contact
10 rue Mercoeur
75011 PARIS
France
Directeur Commercial et Marketing
About us
Miltenyi Biotec is a German biotechnology company, founded in 1989, that is innovative, independent, and experiencing significant growth under the leadership of its founder and owner. The Miltenyi Biotec group currently comprises over 3,900 employees across nearly 25 countries worldwide, including 850 researchers based at our campus in Bergisch Gladbach near Cologne, Germany.
Miltenyi Biotec's portfolio of solutions provides innovative tools for translating basic research into cellular therapy. The company offers techniques for sample preparation, cell separation and analysis, molecular analysis, cell culture, and therapeutic apheresis.
Business offer
Our mission is to advance scientific understanding and medicine by providing solutions for cell and gene therapy and biomedical research from basic research to commercial-scale cell therapy manufacturing. We offer innovative technologies for Sample Preparation, Cell Separation, Cell Culture, Flow Cytometry, Imaging & Cell & Gene therapy.
Activities
- Technology Supplier
- Genetic Diseases
- Oncology
- Nervous Central System
- Infectiology
- Immunology
- Target selection & validation
- Gene / protein discovery
- bioinformatics design
- Expression and pathway analysis of target
- quantification of target
- Immunotherapy lead generation
- Manufacturability
- Production quality
- CMC feasibility
- Cell activation
- Cell-based activation (APCs, AAPCs)
- Bead-base activation
- Antibody-based activation
- Ex-vivo activation (cell transfer)
- Gene modification / Transduction
- Retroviral & lentiviral vectors
- mRNA electroporation
- Preclinical biomarkers
- Mechanism/Function
- Mechanism of action
- PK/PD features
- Exploratory toxicology
- Drug-Target interaction
- Level of response duration
- Specificity
- Surrogate markers
- CMC
- GLP compliance
- GLP compliance
- Master Cell Bank
- Production
- Characterization
- Storage
- Analytical development
- Cell Culture
- Gene modification / Transduction
- Retroviral & lentiviral vectors
- Cell expansion
- Bioproduction
- Batches production type
- Mammalian
- GLP compliance
- GMP compliance
- Pilot Batches
- Tests
- Optimization
- Scale-Up process
- Process optimization & validation
- Volume
- Preclinical / Tox
- Commercial
- USP (Scale-Up)
- Cell expansion
- Inoculation
- Low volume containers to Bioreactors
- DSP (Recovery)
- Harvest
- Filtration
- Purification
- Fill & Finish
- Aseptic filling
- Cell origin
- Single donor
- Pool of donors
- Cell Banking
- IPs
- MSC
- CD34 + HSC cells
- Tissue acquisition
- Apheresis
- Target cell isolation
- iPS reprogramming
- Differentiated Cell
- Production Cell
- Safety donor-derived therapies
- Cell modification
- Direct reprogramming
- Cell Activation
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- CMC/analytical quality assessment, quality control
- Cleaning
- Bioproduction engineering
- Cell Expansion
- Stirred tank Bioreactor
- Cell factory
- Organoids culture
- Scale-Up
- Process optimization
- Automated manufacturing
- On-line monitoring
- Non-GMP expansion
- GMP expansion
- Other
- Purification/Extraction
- Centrifugation
- CGMP
- Formulation
- Target Identification
- Gene / protein discovery
- Expression and pathway analysis of target
- quantification of target
- Gene Cloning
- Gene augmentation
- Gene inhibition
- Killing Gene
- KI / KO
- (Gene) engineering
- CRISPR activation
- CRISPR interference
- TRAC gene editing
- TALEN
- Gene Delivery System
- Lentivirus
- Electroporation
- CAR Construction
- T-cell activation/transduction
- Engineering
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- Bioproduction/CMC/Analytical Quality Assessment, Quality Control
- Bioproduction
- Scale-Up
- Automated manufacturing
- Tracking process
- Non-GMP pilot batch
- GMP batch
- Cleaning
- CGMP
- Quality control
